American pharmaceutical giant Pfizer confirmed on Friday that 58 positions are at risk at its Belgian headquarters, following the announcement of a restructuring plan aimed at improving “operational efficiency.”
The decision was disclosed during a works council meeting, where the company outlined its intention to reduce its workforce in Belgium. Out of 300 jobs, nearly one-fifth could be cut, affecting various departments.
Unions Condemn Repeated Layoffs
Belgian trade unions ABVV and ACV strongly criticized the decision, arguing that Pfizer continues to generate massive profits worldwide while “bleeding its Belgian employees dry.” They expressed frustration that this restructuring represents the second collective redundancy in just two years.
In a joint statement, the unions highlighted the company’s role during the COVID-19 pandemic, when Pfizer was hailed globally for its life-saving vaccines. “It is shocking that a company of such wealth, once celebrated during the pandemic, is now slashing jobs year after year worldwide,” the statement read.
Company Defends Decision
Pfizer defended the restructuring as part of a broader strategy to streamline operations and remain competitive in an evolving pharmaceutical market. The company stressed that the cuts were not a reflection of local performance but rather a global measure to optimize resources.
Despite the backlash, Pfizer reaffirmed its commitment to maintaining a strong presence in Belgium, which plays a key role in the company’s European operations and research activities.
Economic and Social Impact
The job cuts add to growing concerns over employment stability in the pharmaceutical industry, a sector that has seen several waves of restructuring in recent years. Workers and unions fear the trend will undermine Belgium’s role as a hub for pharmaceutical research and development.
Local authorities have yet to comment formally on Pfizer’s announcement, but political pressure is expected to mount as unions call for government intervention to protect jobs and ensure fair treatment for employees.
Broader Context
Globally, Pfizer has faced restructuring efforts following its record revenues during the COVID-19 crisis. With declining vaccine sales and a shifting healthcare landscape, the company has moved to cut costs, consolidate operations, and refocus investments.
For Belgian employees, however, the decision brings renewed uncertainty and disappointment. As unions prepare to negotiate with management, questions remain about how many of the 58 at-risk positions can be saved and what the long-term future holds for Pfizer’s operations in the country.
